Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
CHICAGO – Progression-free survival results for Johnson & Johnson's anti-CD-38 antibody Darzalex (daratumumab) in the CASTOR study are highly competitive with other myeloma drugs and represent a change in the standard of care, the trial's lead investigator said on June 5 at the American Society of Clinical Oncology annual meeting.
One of the major data highlights at the American Society of Clinical Oncology meeting, held June 3-7 in Chicago, is...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
